Subscribe to Newsletter

Optimizing Downstream Processing for an Inactivated Rabies Vaccine


Youness Cherradi, PhD, Senior Process Development Scientist, EMEA, Bioprocessing
Youssef Gaabouri, Associate Director Sales, North & West Africa, Bioprocessing
Anissa Boumlic, PhD, Head of Global Vaccine & Plasma Segments, Bioprocessing

Institut Pasteur de Tunis:

Héla Kallel, PhD, Head of the Biotechnology Development Group
Khaled Trabelsi, PhD, Senior Engineer, interim Head of the Biotechnology Development Group

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Related White Papers
A Fast and High Precision Influenza Vaccine Potency Assay

| Contributed by ForteBio

Total virus titer in minutes

| Contributed by Malvern Panalytical

Measurement of the concentration of Adeno-Associated Virus

| Contributed by Malvern Panalytical

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine